Unmet needs in HER2+ MBC

ASCO 2022 Conference Coverage
E

Lecture Summary - ASCO 2022 Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Unresectable and/or Metastatic Breast Cancer: Safety Follow-Up of the Phase 3 DESTINY-Breast03

By ASCO 2022 Conference Coverage FEATURING Erika Hamilton
By ASCO 2022 Conference Coverage FEATURING Erika Hamilton
413 views
June 13, 2022
Comments 0
Login to view comments. Click here to Login
18:35

Management of HER2+ mBC With Brain Metastases

Carmen Criscitiello

227 views
07:01

Update on T-DXd vs. T-DM1 in Pts with HER2+ MBC: Results of the DEST…

Javier Cortes

421 views
10:48

Update on T-DXd vs. T-DM1 in HER2+ MBC: Subgroup Analyses From the P…

SABCS 2021 Conference Coverage on VuMedi

S. Hurvitz

904 views
31:25

Treating HER2+ BC in the Metastatic Setting

Total Health

R. L. Mahtani

373 views
19:28

Management of Metastatic HER2+ Breast Cancer

Margaret Gatti-Mays

482 views
09:57

ASCO 2022 Preliminary Analysis of an Expanded Access Study of the Fi…

ASCO 2022 Conference Coverage

C. Dang

198 views
01:06

Lecture Summary - ASCO 2022 Preliminary Analysis of an Expanded Acce…

ASCO 2022 Conference Coverage

C. Dang

40 views
11:56

ASCO 2022 on Monitoring and Management of Interstitial Lung Disease/…

ASCO 2022 Conference Coverage

B. Feinberg

337 views
01:17

Lecture Summary - ASCO 2022 on Monitoring and Management of Intersti…

ASCO 2022 Conference Coverage

B. Feinberg

21 views
50:05

Integrative Medicine Through the Lens of Systems Biology: Implicatio…

Moffitt Cancer Center

D. Tripathy

185 views
11:47

Optimizing Treatment Options in HER2+mBC With Brain Metastasis

Jane Meisel

226 views
34

Lecture Summary - Optimizing Treatment Options in HER2+mBC With Brai…

Jane Meisel

28 views